Pharmaceutical Composition For Preventing Or Treating Tuberculosis

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating tuberculosis, comprising: (a) a pharmaceutically effective amount of a compound represented by the following chemical formula 1; and (b) a pharmaceutically acceptable carrier. Chemical formula 1 The compound contained as an active ingredient of the present invention inhibits the expression and activity of CO-DH in tubercle bacillus so as to effectively block the detoxification of carbon monoxide, which is an important survival factor of tubercle bacillus, and is safe for the human body since the compound targets CO-DH which does not exist in the human body. In addition, the compound creates a synergistic effect when combined with a conventional tuberculostatic drug, and thus can be more effective for treating tuberculosis.

Description

CROSS REFERENCE TO RELATED APPLICATIONS AND CLAIM OF PRIORITY

[0001] This patent application claims benefit under 35 U.S.C. 119(e), 120, 121, or 365(c), and is a National Stage entry from International Application No. PCT/KR2012/001122, filed 13 Feb. 2013, which claims priority to Korean Patent Application No. 10-2012-0025449, filed Mar. 13, 2012, entire contents of which are incorporated herein by reference.

BACKGROUND

[0002] 1. Technical Field

[0003] The present invention relates to a pharmaceutical composition for preventing or treating tuberculosis based on the inhibition on carbon monoxide dehydrogenase in Mycobacterium tuberculosis.

[0004] 2. Background Art

[0005] Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis. Tuberculosis is one of the main diseases in developing countries and its seriousness has been increased also in advanced countries. Approximately 8 million new patients are found and approximately 3 million patients die each year. Tuberculosis may be asymptomatic for a considerable period of time even after infection. However, this disease commonly gives rise to acute inflammation of the lungs and then thermal and non-productive cough. Moreover, tuberculosis, if not treated, may typically cause serious complications, leading to death.

[0006] Recently, Mycobacterium tuberculosis has grown in importance since some cases of infection with Mycobacterium tuberculosis strains having resistance against both the HIV pandemic and several kinds of drugs have been reported. According to the researches on antibiotic-resistant Mycobacterium tuberculosis over last five years in 35 countries, Mycobacterium tuberculosis having resistance to one or more drugs is approaching 36%, and multidrug-resistant Mycobacterium tuberculosis (MDR-TB), which shows resistance to two or more antibiotics including rifampin (RMP), is about 36%. These figures indicate serious levels. Approximately 9.9% of patients even without a history of tuberculosis treatment show resistance to at least one drug. As such, drug-resistant tuberculosis and multi-drug resistant tuberculosis increase treatment costs as well as lower treatment efficiency, and eventually become a great threat to patients, such as developing into incurable tuberculosis. The existing tuberculosis treatments generally require a long period of time, one to two years. Here, combined administration of three or four drugs is recommended since the use of one or two antitubercular agents induces fast resistance. However, the long-term use of antitubercular agents strains the liver, causing side effects, such as liver cirrhosis and jaundice. Moreover, for the treatment of multi-drug resistant tuberculosis, secondary antitubercular agents, which are relatively less effective, induce more side effects, and are expensive, need to be used. Accordingly, for the tuberculosis elimination strategy for improving treatment efficiency of the multi-drug resistant tuberculosis, new drugs capable of treating even latent tuberculosis, being more effective, having less side effects, and exhibiting efficacy for a short period of time are required to be developed.

[0007] Although antitubercular agents that are harmless to humans, more effective, and act quickly are urgently required to be developed as described above, the currently developed drugs do not exhibit great effects in tuberculosis treatment.

[0008] However, the DNA sequence of Mycobacterium tuberculosis was established, which opened the possibility to find targets of new drugs. Recently, an inhibitor against expression and activation of carbon monoxide dehydrogenase (CO-DH) is emerging as a new tuberculosis treatment agent.

[0009] In general, macrophages inhibit bacterial multiplication through various methods, which include a method in which phagolysosome formed by the fusion of phagosome with lysosome uses protease in the lysosome to remove microorganisms and a method in which bactericidal reactive oxygen and nitrogen species secreted by IFN-.gamma. stimulation remove microorganisms. The reactive nitrogen species is the key material in innate immunity. The reactive nitrogen species contains NO and its derivatives. NO is produced from the degradation of L-arginine by inducible nitric oxide synthase (iNOS). NO derivatives, such as HNO.sub.2 and HNO.sub.3, play an important role in the control of intracellular parasitic bacteria such as Mycobacterium tuberculosis and the like, or cancer cells. Here, Mycobacterium tuberculosis survives against various bactericidal mechanisms of macrophages, causing diseases in hosts.

[0010] Meanwhile, carboxydobacteria are a group of bacteria which are able to grow by using carbon monoxide (CO) as the sole energy and carbon source. The main enzyme for the oxidation of CO in the carboxydobacteria is CO-DH. CO-DH oxidizes CO into carbon dioxide (CO.sub.2) to generate two electrons by using water as an oxidant. Here, CO.sub.2 is converted into cellular components through the Calvin cycle, and the electrons are used to energy production through oxidative phosphorylation in the electron transport chain.

[0011] It was recently founded that Mycobacterium sp. strain JC1, which is evolutionarily far away from the known carboxydobacteria, has CO-DH activity, and CO-DH genes were cloned and DNA-sequenced therefrom. This facilitates the study of CO-DH activities for various species of the genus Mycobacterium, and it was found that, besides Mycobacterium sp. strain JC1, many species exhibit CO-DH activity. In addition, gene sequencing of some of the previously identified mycobacteria, including Mycobacterium tuberculosis H37Rv, revealed that open reading frames (OFRs) similar to those of the CO-DH genes of Mycobacterium sp. strain JC1 are conserved in these bacteria. In CO-DH genes of the mycobacteria, three genes seem to be clustered in the order of cutB-cutC-cutA to constitute one operon.

[0012] In addition, CO-DH activity on NO was studied from the understanding of structural similarity between CO and NO used as substrates of CO-DH. As a result, it was observed that CO-DH also possesses activity of nitric oxide dehydrogenase (NO-DH) that uses NO as a substrate.

[0013] Based on the existing studies, in order to find the relation between NO-DH activity that is exhibited by CO-DH and the intramacrophage survival mechanism of Mycobacterium tuberculosis, the present inventors constructed mutants of several species of mycobacteria including Mycobacterium tuberculosis H37Rv with respect to CO-DH genes, and established intramacrophage survival-associated characteristics of the mutants.

[0014] As a result, in the case of Mycobacterium tuberculosis H37Rv, CO-DH activity was observed in only the wild type but not the mutant. Further, it was verified that the intramacrophage survival rate was remarkably reduced in the mutant of Mycobacterium tuberculosis H37Rv as compared with the wild type.

[0015] These results present a new approach to safe antitubercular agents capable of promoting a complete cure of tuberculosis and reducing tissue damages by inhibiting metabolisms associated with the survival of Mycobacterium tuberculosis to suppress survival and growth of Mycobacterium tuberculosis.

[0016] Throughout the entire specification, many papers and patent documents are referenced and their citations are represented. The disclosures of cited papers and patent documents are entirely incorporated by reference into the present specification, and the level of the technical field within which the present invention falls and details of the present invention are explained more clearly.

SUMMARY

[0017] The present inventors endeavored to develop antitubercular agents that are more effective and safer for humans as compared with the existing antitubercular agents. As a result, the present inventors presented CO-DH present in currently unknown Mycobacterium tuberculosis for new antitubercular agents, and screened compounds, which inhibit activity and expression of CO-DH to effectively block the detoxification of carbon monoxide as an important factor in the survival of Mycobacterium tuberculosis, from the compound libraries. The anti-tuberculosis compounds of the present invention target CO-DH absent in humans and thus are safe for humans, which was verified by a cytotoxicity test. Further, the present inventors verified that the anti-tuberculosis compounds of the present invention create a synergistic effect at the time of combined administration with the existing anti-tuberculosis agents, thereby achieving a more effective treatment of tuberculosis, and thus completed the present invention.

[0018] Therefore, the present invention has been made in view of the above-mentioned problems, and an aspect of the present invention is to provide a pharmaceutical composition for preventing or treating tuberculosis.

[0019] Another aspect of the present invention is to provide a method for preventing or treating tuberculosis.

[0020] Still another aspect of the present invention is to provide a use for preparing a pharmaceutical composition for preventing or treating tuberculosis.

[0021] Other purposes and advantages of the present disclosure will become clarified by the following detailed description of invention, claims, and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] FIG. 1 shows locations of primers used in examples of the present invention.

[0023] FIG. 2 shows a construction procedure of plasmid pSW84 used in examples of the present invention.

[0024] FIG. 3 shows amino acid sequences of intact CutA of Mycobacterium sp. strain JC1 wild type and CutA with a deletion of Mycobacterium sp. strain JC1 cutA.sup.- mutant. Deleted amino acids were expressed as a line (-).

[0025] FIG. 4 shows a gel image of Mycobacterium sp. strain JC1 cutA1.sup.- mutant confirmed by PCR. Lane 1 represents 1-kb ladder; Lane 2, 4,251-bp PCR product obtained from chromosomal DNA of Mycobacterium sp. strain JC1 wild type by using primers cutR-for and cutA-rev; Lane 3, 2,850-bp PCR product obtained from chromosomal DNA of Mycobacterium sp. strain JC1 cutA1.sup.- mutant by using primers cutR-for and cutA-rev; Lane 4, 4,482-bp PCR product obtained from chromosomal DNA of Mycobacterium sp. strain JC1 wild type by using primers orf1-for and cutA-rev; and Lane 5, 4,482-bp PCR product obtained from chromosomal DNA of Mycobacterium sp. strain JC1 cutA1.sup.- mutant by using primers orf1-for and cutA-rev.

[0026] FIG. 5 shows a result of Mycobacterium sp. strain JC1 cutA1.sup.-/A2.sup.- mutant confirmed by PCR. Lane 1 represents 1-kb ladder; Lane 2, 3,185-bp PCR product obtained from chromosomal DNA of Mycobacterium sp. strain JC1 wild type by using primers cutA-for and orf2-rev; Lane 3, 3,185-bp and 1,784-bp PCR products obtained from chromosomal DNA of Mycobacterium sp. strain JC1 cutA1.sup.- mutant by using primers cutA-for and orf2-rev; and Lane 4, 1,784-bp PCR product obtained from chromosomal DNA of Mycobacterium sp. strain JC1 cutA1.sup.-/A2.sup.- mutant by using primers cutA-for and orf2-rev.

[0027] FIG. 6 shows growth curves of Mycobacterium sp. strain JC1 wild type ( ), cutA1.sup.- mutant (.largecircle.), and cutA1.sup.-/A2.sup.- mutant ().

[0028] FIG. 7 shows results of staining based on CO-DH activity for cell extracts of Mycobacterium sp. strain JC1 wild type (Lane 1), cutA1.sup.- mutant (Lane 2), and cutA1.sup.-/A2.sup.- mutant.

[0029] FIG. 8 shows results of western blotting of Mycobacterium sp. strain JC1 wild type (Lane 1), cutA1.sup.- mutant (Lane 2), and cutA1.sup.-/A2.sup.- mutant (Lane 2).

[0030] FIG. 9 shows growth curves of Mycobacterium sp. strain JC1 wild type ( ), cutA1.sup.-/A2.sup.- mutant (), and complemented cutA1.sup.-/A2.sup.- mutant (.largecircle.).

[0031] FIG. 10 shows results of staining based on CO-DH activity of Mycobacterium sp. strain JC1 wild type (Lane 1) and complemented cutA1.sup.-/A2.sup.- mutant (Lane 2) grown in the SMB-CO medium.

[0032] FIG. 11 shows results of the inhibition on CO-DH activity for libraries of Korea Chemical Bank.

[0033] FIGS. 12a to 12c shows results of survival rates of Mycobacterium sp. strain JC1 wild type, and, for CO-DC subunits, cutA mutant and complemented cutA mutant, which were treated with 10 mM of NaNO.sub.2 and the compounds of the present invention and then plated on plate media. FIG. 12a shows results for 12.12.5 .mu.M of the compounds of the present invention; FIG. 12b, 25.0 .mu.M; and FIG. 12c, 50 .mu.M.

[0034] FIGS. 13a to 13c show results of survival rates of Mycobacterium tuberculosis in marrow cell-derived macrophages after treatment with the compounds of the present invention and the control compounds. FIGS. 13a and 13b show results for the compounds of the present invention and FIG. 13c shows results for the control compounds.

DETAILED DESCRIPTION

[0035] In accordance with an aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating tuberculosis, the composition including: (a) a pharmaceutically effective amount of a compound represented by Formula 1 below; and (b) a pharmaceutically acceptable carrier:

##STR00001##

wherein in Formula 1, R.sub.1 is

##STR00002##

R.sub.2 is H, a hydroxyl, halogen, C.sub.1-C.sub.10 alkyl, C.sub.3-C.sub.15 cycloalkyl, C.sub.2-C.sub.10 alkenyl, or C.sub.1-C.sub.8 alkoxy; A and B each are independently CH or N; and n is an integer of 1 to 5, and wherein in R.sub.1, R.sub.3 and R.sub.4 each are independently H, hydroxyl, halogen, C.sub.1-C.sub.10 alkyl, or C.sub.3-C.sub.15 cycloalkyl.

[0036] In accordance with another aspect of the present invention, there is provided a method for preventing or treating tuberculosis, the method including administering to a subject a pharmaceutical composition containing: (a) a pharmaceutically effective amount of a compound represented by Formula 1 above; and (b) a pharmaceutically acceptable carrier.

[0037] In accordance with still another aspect of the present invention, there is provided a pharmaceutical composition including: (a) a pharmaceutically effective amount of a compound represented by Formula 1 above; and (b) a pharmaceutically acceptable carrier, for preventing or treating tuberculosis.

[0038] In accordance with still another aspect of the present invention, there is provided a use for preparing a pharmaceutical composition for preventing or treating tuberculosis, the composition including: (a) a pharmaceutically effective amount of a compound represented by Formula 1 above; and (b) a pharmaceutically acceptable carrier.

[0039] The present inventors endeavored to develop antitubercular agents that are more effective and safer for humans as compared with the existing antitubercular agents. As a result, the present inventors presented CO-DH present in currently unknown Mycobacterium tuberculosis for new antitubercular agents, and screened compounds, which inhibit activity and expression of CO-DH to effectively block the detoxification of carbon monoxide as an important factor in the survival of Mycobacterium tuberculosis, from the compound libraries. The anti-tuberculosis compounds of the present invention target CO-DH absent in humans and thus are safe for humans, which was verified by a cytotoxicity test. Further, the present inventors confirmed that the anti-tuberculosis compounds of the present invention create a synergistic effect at the time of combined administration with the existing anti-tuberculosis, thereby achieving more effective treatment of tuberculosis, and thus completed the present invention.

[0040] The compound used as an active ingredient in the pharmaceutical composition of the present invention is represented by Formula 1. In Formula 1 defining the compound of the present invention, the term "C.sub.1-C.sub.10 alkyl" refers to a straight or branched chain saturated hydrocarbon group having 1 to 10 carbon atoms, and represents preferably "C.sub.1-C.sub.6 straight or branched chain alkyl", and more preferably "C.sub.1-C.sub.3 straight or branched chain alkyl", which is a lower alkyl and includes methyl, ethyl, n-propyl, and isopropyl.

[0041] As used herein, the term "C.sub.3-C.sub.15 cycloalkyl" refers to a saturated monocyclic or polycyclic hydrocarbon group having 3 to 15 carbon atoms, and includes, for example, a cyclopropyl ring, a cyclobutyl ring, a cyclohexyl ring, a cycloheptyl ring, or the like, but is not limited thereto.

[0042] As used herein, the term "C.sub.2-C.sub.10 alkenyl" refers to a straight or branched chain alkenyl having 2 to 10 carbon atoms and at least one carbon-carbon double bond, and includes for example, vinyl, allyl, 2-butenyl, 3-butenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, and the like, but is not limited thereto.

[0043] As used herein, the term "C.sub.1-C.sub.8 alkoxy" includes, for example, methoxy, ethoxy, propoxy, and the like, but is not limited thereto.

[0044] As used herein, the term "halogen" includes F, Cl, Br, and I.

[0045] According to a preferable embodiment of the present invention, the compound represented by Formula 1 is a compound represented by Formula 2 below:

##STR00003##

wherein in Formula 2, R.sub.2 is H, hydroxyl, halogen, or C.sub.1-C.sub.10 alkyl; A and B each are independently CH or N; n is an integer of 1 to 3; and R.sub.3 is H, hydroxyl, halogen, or C.sub.1-C.sub.10 alkyl.

[0046] According to another preferable embodiment of the present invention, the compound represented by Formula 1 is a compound represented by Formula 3 below:

##STR00004##

wherein in Formula 3, R.sub.2 is H, hydroxyl, halogen, or C.sub.1-C.sub.10 alkyl; A and B each are independently CH or N; n is an integer of 1 to 3; and R.sub.3 and R.sub.4 each are independently H, hydroxyl, halogen, or C.sub.1-C.sub.10 alkyl.

[0047] According to a more preferable embodiment of the present invention, the compound represented by Formula 2 is a compound represented by Formula 4 below:

##STR00005##

According to still another preferable embodiment of the present invention, the compound represented by Formula 3 is a compound selected from the group consisting of compounds represented by Formulas 5 to 7 below:

##STR00006##

[0048] According to still another preferable embodiment of the present invention, the compound which is included as an active ingredient of the present invention inhibits the transcription of CO-DH genes.

[0049] According to still another preferable embodiment of the present invention, the compound which is included as an active ingredient of the present invention inhibits the expression of CO-DH genes.

[0050] The compound represented by General Formula 1 of the present invention was screened from the representative library and the natural product library (7841 compounds in total) of Korea Chemical Bank by evaluating the inhibition on CO-DH activity through the CO-DH assay. The compound represented by General Formula 1 of the present invention inhibits CO-DH activity of Mycobacterium tuberculosis that detoxificates NO and CO generated in microphages.

[0051] The test material analyzed by the screening method of the present invention is a single compound or a mixture of compounds (e.g., a natural extract or a cell or tissue culture). The test material may be obtained from a library of synthetic or natural compounds. The method of obtaining the library of such compounds is known in the art. The library of synthetic compounds is commercially available from Maybridge Chemical Co. (UK), Comgenex (USA), Brandon Associates (USA), Microsource (USA) and Sigma-Aldrich (USA), and the library of natural compounds is commercially available from Pan Laboratories (USA) and MycoSearch (USA).

[0052] The test material may be obtained through various known combinational library methods known in the art. For example, it may be obtained by a biological library method, a spatially-addressable parallel solid phase or solution phase library method, a synthetic library method requiring deconvolution, a "one-bead one-compound" library method, and a synthetic library method using affinity chromatography selection. The methods of obtaining the molecule libraries are described in DeWitt et al., Proc. Natl. Acad. Sci. U.S.A. 90:6909(1993); Erb et al. Proc. Natl. Acad. Sci. U.S.A. 91:11422(1994); Zuckermann et al., J. Med. Chem. 37:2678(1994); Cho et al., Science 261:1303(1993); Carell et al., Angew. Chem. Int. Ed. Engl. 33:2059(1994); Carell et al., Angew. Chem. Int. Ed. Engl. 33:2061; Gallop et al., J. Med. Chem. 37:1233(1994); and the like.

[0053] According to another preferable embodiment of the present invention, the tuberculosis that is to be prevented or treated by the pharmaceutical composition of the present invention is eye tuberculosis, skin tuberculosis, adrenal tuberculosis, renal tuberculosis, epididymal tuberculosis, lymphatic gland tuberculosis, laryngeal tuberculosis, middle ear tuberculosis, intestinal tuberculosis, multidrug-resistant tuberculosis, pulmonary tuberculosis, sputum tuberculosis, bone tuberculosis, throat tuberculosis, lymphatic tuberculosis, lung deficiency, breast tuberculosis, or spinal tuberculosis.

[0054] The composition of the present invention may be more effectively used in the treatment of the above-mentioned tuberculosis through a synergistic effect with the existing antitubercular agents.

[0055] As used herein, the term "pharmaceutically effective amount" refers to an amount enough to attain efficacy or activity of the compound of Chemical Formula 1.

[0056] When the composition of the present invention is prepared as a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier included in the pharmaceutical composition of the present invention is one conventionally used in formulations, and examples thereof may include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. The pharmaceutical composition of the present invention may further include, besides the above components, a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like. Suitable pharmaceutically acceptable carriers and agents are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0057] The pharmaceutical composition of the present invention may be administered orally or parenterally. Examples of parenteral administration may include intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal injection, mucosal administration, administration of eye drops, and the like.

[0058] A suitable administration dose of the pharmaceutical composition of the present invention may be varied depending on various factors, such as method of formulation, manner of administration, age, body weight, sex, and morbidity of the patient, diet, route of administration, excretion rate, and response sensitivity. Preferably, the suitable administration dose is 0.0001 to 100 mg/kg (body weight) in adults.

[0059] The pharmaceutical composition of the present invention may be formulated into a unit or multiple dosages form using a pharmaceutically acceptable carrier and/or excipient according to the method easily conducted by a person having ordinary skill in the art to which the present invention pertains. Here, the dosage form may be a solution in an oily or aqueous medium, a suspension, a syrup, or an emulsion, an extract, a powder, a granule, a tablet, or a capsule, and may further include a dispersant or a stabilizer.

[0060] Features and advantages of the present invention are summarized as follows:

[0061] (i) The present invention is directed to antitubercular agents containing compounds that inhibit activity and expression of CO-DH to effectively block the detoxification of carbon monoxide as an important factor in the survival of Mycobacterium tuberculosis.

[0062] (ii) The anti-tuberculosis compounds of the present invention target CO-DH that absent in humans and thus are safe for humans, which was confirmed by a cytotoxicity test.

[0063] (iii), Further, the anti-tuberculosis compounds of the present invention create a synergistic effect at the time of combined administration with the existing anti-tuberculosis, thereby achieving more effective treatment of tuberculosis.

[0064] Hereinafter, the present invention will be described in detail with reference to examples. These examples are only for illustrating the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.

EXAMPLES

Example 1

Preparation of Mycobacterium sp. Strain JC1 cutA Mutants

[0065] 1. Methods

[0066] (1) Construction of Vector for Mutant Preparation

[0067] The 2.543-bp DNA fragment prepared by digestion of pTS8 with both of the restriction enzymes PvuII and EcoRV was ligated to pBluescript II SK(+), thereby obtaining pSW49. The 5,056-bp DNA fragment prepared by digestion of the pSW49 with the restriction enzyme PvuII and the 4,424-pb DNA fragment prepared by digestion of pTS16 with the restriction enzyme PvuII were ligated to obtain pCODH. The 6,889-bp and 1,190-bp DNA fragments, which were prepared by digestion of the pCODH with the restriction enzyme EcoRV, were ligated to obtain pSW79 containing the cutA gene with a 1,401-bp in-frame deletion. In order to insert the pSW79 into pKO that contains a hygromycin-resistant gene and a sacB gene and is usable as a suicide vector in Mycobacterium sp. strain JC1 (Sherman et al., 2001), the 3,222-bp DNA fragment prepared by digestion of the pSW79 with the restriction enzyme SacI was blunt-ended with the enzyme Klenow, and then inserted into a partial fragment prepared by digestion of the pKO with the restriction enzyme SmaI, thereby obtaining pSW84 (FIG. 2).

[0068] (2) Preparation and Verification of Mutants

[0069] a. Preparation and Isolation of Mycobacterium sp. Strain JC1 cutA1 or cutA2 Mutant

[0070] In order to obtain a mutant (cutA1.sup.- or cutA2.sup.-) in which one of two cutA genes (cutA1 and cutA2) constituting two copies of CO-DH genes (copy I and copy II) present in Mycobacterium sp. strain JC1 has an inframe deletion, competent cells prepared by using wild type Mycobacterium sp. JC1 were transformed with pSW84 by electroporation. Then, the transformed strain was plated on the 7H9-glucose solid medium containing hygromycin (76 .mu.g/ml). The culturing was performed at 37.degree. C. for 4 days to obtain a single-crossover mutant. The obtained single-crossover mutant was cultured in the 7H9-glucose liquid medium free from hygromycin at 37.degree. C. and 200 rpm for 7 days, and then 30 .mu.l of the culture liquid was plated on the 7H9 solid medium supplemented with 10% (w/v) sucrose. The culturing was performed at 37.degree. C. for 4 days to obtain a double-crossover mutant.

[0071] b. Verification of Mutant with a Deletion in One cutA Gene

[0072] In order to verify whether the obtained Mycobacterium sp. strain JC1 mutant is cutA1.sup.- mutant or cutA2.sup.- mutant, PCR amplification of chromosomal DNA extracted from the obtained mutant was performed by using primers cutR-for (5'-gagccccgacgacgttcggg-3') and cutA-rev (5'-cagatcggcggggtcgctctg-3') or orf1-for (5'-ggcgtgggtatggaggtctt-3') and cutA-rev (5'-cagatcggcggggtcgctctg-3').

[0073] In the case of PCR using the primers cutR-for (5'-gagccccgacgacgttcggg-3') and cutA-rev (5'-cagatcggcggggtcgctctg-3'), the 2,850-bp PCR product, which is shortened by 1,401 bp as compared with the wild type (4,251-bp PCR product), will be produced if mutation occurs in the cutA1 gene. In the case of PCR using the primers orf1-for (5'-ggcgtgggtatggaggtctt-3') and cutA-rev (5'-cagatcggcggggtcgctctg-3'), the 3,081-bp PCR product, which is shortened by 1,401 bp as compared with the wild type (4,482-bp PCR product), will be produced if mutation occurs in the cutA2 gene.

[0074] c. Preparation and Isolation of Mycobacterium sp. Strain JC1 cutA1.sup.-/A2.sup.- Mutant

[0075] Competent cells prepared by using the mutant in which mutation occurs in one cutA gene were transformed with pSW84 by electroporation. Then, the transformed strain was plated on the 7H9-glucose solid medium containing hygromycin (75 .mu.g/ml). The culturing was performed at 37.degree. C. for 4 days to obtain a single-crossover mutant. The obtained single-crossover mutant was cultured in the 7H9-glucose liquid medium free from hygromycin at 37.degree. C. and 200 rpm for 7 days, and then 30 .mu.l of the culture liquid was plated on the 7H9 solid medium supplemented with 10% (w/v) sucrose. The culturing was performed at 37.degree. C. for 4 days to obtain a double-crossover mutant.

[0076] d. Verification of Mycobacterium sp. Strain JC1 cutA1.sup.-/A2.sup.- Mutant

[0077] In order to confirm Mycobacterium sp. strain JC1 cutA1.sup.-/A2.sup.- mutant, PCR amplification of chromosomal DNA extracted from the obtained mutant was performed by using primers cutA-for (5'-gcatgacgactgcagacgtta-3') and orf2-rev (5'-gtcactcgtgaccgcagcat-3'), which are commonly present in copy I and copy II of CO-DH genes. Only the 1,784-bp PCR product, which is shortened by 1,401 bp as compared with the wild type (3,185-bp PCR product), will be produced if mutation occurs in both the cutA1 and cutA2 genes. Both of the 3,185-bp PCR product and 1,784-bp PCR product will be produced for the Mycobacterium sp. strain JC1 cutA1 or cutA2 mutant.

[0078] 2. Results

[0079] 1) Construction of Vector for Mutant Induction

[0080] The vector pSW84 for inducing a mutant having a 1,401-bp inframe deletion in the cutA gene as compared with the wild type cutA gene was constructed (FIG. 2). The portion which is deleted from the vector for mutant induction, pSW84, contains a binding region of cutA with molybdopterin cytosine dinucleotide (MCD), which is considered to be important in the binding with CO, and a binding region of cutA genes for a dimer structure (Dobbek et al., 1999) (FIG. 3). Thus, Mycobacterium sp. strain JC1 cutA1.sup.-/A2.sup.- mutant is determined to be impaired since cutA genes do not constitute a dimer structure and the binding with CO is impossible.

[0081] 2) Isolation and Verification of Mycobacterium sp. Strain JC1 cutA1.sup.- Mutant

[0082] A mutant with a deletion in one cutA gene, which was obtained by introducing the prepared pSW84 into the Mycobacterium sp. strain JC1 wild type through electroporation, was isolated. In order to verify whether the isolated mutant is cutA1.sup.- mutant or cutA2.sup.- mutant, PCR amplification of chromosomal DNA extracted from the isolated mutant was performed. The 2,850-bp PCR product was obtained for the primers cutR-for (5'-gagccccgacgacgttcggg-3') and cutA-rev (5'-cagatcggcggggtcgctctg-3') and the 4,482-bp PCR product was obtained for the primers orf1-for (5'-ggcgtgggtatggaggtctt-3') and cutA-rev (5'-cagatcggcggggtcgctctg-3'). Thus, it was verified that the isolated mutant was cutA1.sup.- mutant (FIG. 4) This result was again verified by cloning of the PCR product into the pGEM T-easy vector and sequencing thereof.

[0083] 3) Isolation and Verification of Mycobacterium sp. Strain JC1 cutA1.sup.-/A2.sup.- Mutant

[0084] The cutA1.sup.-/A2.sup.- mutant was isolated by introducing of the prepared pSW84 into the cutA1.sup.- mutant by electroporation. In order to verify whether the isolated mutant is the cutA1.sup.-/A2.sup.- mutant with a deletion in both two cutA genes, PCR amplification of chromosomal DNA extracted from the isolated mutant was performed. Only the 1,784-bp PCR product, which was shortened by 1,401 bp as compared with the 3,185-bp PCR product, was obtained for the primers cutA-for (5'-gcatgacgactgcagacgtta-3') and orf2-rev (5'-gtcactcgtgaccgcagcat-3'). Thus, it was verified that the isolated mutant was cutA1.sup.-/A2.sup.- mutant (FIG. 5) This result was again verified by cloning of the PCR product into the pGEM T-easy vector and sequencing thereof.

[0085] Further, it was verified that the Mycobacterium sp. strain JC1 cutA1.sup.-/A2.sup.- mutant was not grown in the SMB-CO medium (FIG. 6). Further, the cell extract of the cutA mutant grown in the SMB-glucose medium was subjected to staining based on CO-DH activity (FIG. 7) and western blotting (FIG. 8), and as a result, it was verified that CutA was absent and thus CO-DH activity was not exhibited in the cutA1.sup.-/A2.sup.- mutant.

[0086] 4) Complementation Test of cutA Mutant

[0087] The obtained Mycobacterium sp. strain JC1 cutA1.sup.-/A2.sup.- mutant was complemented by the pTWMA-JC1 (Jung, 004) with cutA gene of Mycobacterium sp. strain JC1. As a result, it was verified that the complemented mutant was grown in the SMB-CO medium (FIG. 9). The complemented mutant was grown in the SMB-glucose medium and then subjected to staining based on CO-DH activity. As a result, it was verified that the complemented mutant possessed CO-DH activity (FIG. 10).

Example 2

Screening of Compounds Through CO-DH Activity Measurement

[0088] (1) Library Compounds

[0089] The inhibition of CO-DH activity was measured for the representative library and the natural product library (7841 compounds in total) of Korea Chemical Bank by three times of CO-DH activity assay for each compound. The measured values were averaged. The results were shown FIG. 11.

[0090] As can be seen from FIG. 11, many kinds of compounds of the compound libraries exhibited the inhibitory effect on CO-DH activity. Among them, Compound 115024 represented by Chemical Formula 1 below was selected as being most effective in tests on the inhibition of enzyme activity and the inhibition of bacteria. After that, its analogs were assayed and approximately 200 kinds of compounds were again provided. Among them, three most effective compounds (114976, 114991, and 127999) were selected wherein the three compounds are represented by Chemical Formulas 2 to 4, respectively:

##STR00007##

[0091] (2) Extraction of Protein

[0092] In order to obtain an enzyme extract to be used for the measurement of CO-DH activity, the bacteria cultured according to respective experiment conditions were collected by centrifugation at 18,000.times.g for 10 minutes at 4.degree. C. (Eppendorf centrifuge-5403, Hamburg, Germany), washed twice with a 50 mM Tris-HCl (pH 7.5) buffer solution, and re-suspended in 3 and of a 50 mM Tris-HCl (pH 7.5) buffer solution. The suspended bacteria were homogenized at 0.degree. C. by repeating 20 times of ultrasonication using an ultrasonic processor (Sonics & Materials Inc., Danbury, Conn.) wherein the ultrasonication was conducted such that ultrasonic wave at 20% amplitude was applied for 3 seconds and paused for 10 seconds. The homogenized culture solution was collected by centrifugation at 18,000.times.g for 30 minutes at 4.degree. C. (Eppendorf centrifuge-5403), and a supernatant was used as an enzyme extract.

[0093] (3) Quantification of Protein

[0094] Proteins were quantified using bovine serum albumin (BSA) as a standard protein according to the method of Bradford (1976).

[0095] (4) Measurement of CO-DH Activity

[0096] CO-DH activity was determined by measuring the reduction rate of 2-(4-indophenyl)-3-(4-nitrophenyl)-2H-tetrazolium chloride (INT, Sigma, .epsilon..sub.496=17.981 mM.sup.-1 cm.sup.-1) in the presence of CO. Here, 1-methoxyphenazine methosulfate (MPMS, Sigma) was used as an electron transfer mediator between CO-DH and INT. A mixture solution of 19.2 ml of 50 mM Tris-HCl (pH 7.5), 250 .mu.l of INT (9.8 mM), 50 .mu.l of MPMS (8.9 mM), and 500 .mu.l of Triton X-100 (25%, v/v) was saturated with CO gas. 800 .mu.l of the resultant solution was added into a plastic cuvette, and then each compound was added thereto to a final concentration of 12.5 .mu.M. Last, 800 .mu.l of the enzyme extract was added thereto, followed by reaction at 30.degree. C. for 200 seconds. Here, the absorbance change is due to red formazan generated resulting from INT reduction, and was measured at 496 nm by using a spectrophotometer (U-2000, Hitachi) equipped with a temperature adjuster. Enzyme specific activity was expressed as nmoles of reduced INT per mg of protein per minute (nmol/mg protein/min). The enzyme specific activity of each compound treatment group was expressed as a percentage of the control group of which enzyme specific activity was set to 100%, and the results were summarized in Table 1.

TABLE-US-00001 TABLE 1 -- Inhibition of CO-DH activity Concentration 12.5 .mu.M Compound 1 (115024) 48 Compound 2 (114976) 18 Compound 3 (114991) 15 Compound 4 (127999) 7

[0097] As can be verified from Table 1 above, the compound of Chemical Formula 1 was the most effective in the inhibition of CO-DH activity, followed by the compounds of Chemical Formulas 2, 3, and 4 in that order.

[0098] (5) Measurement of Survival Rate

[0099] In order to measure the survival rate against NaNO.sub.2 for each bacterium, the modification of KATSUMASA SATO method (1992) was conducted. Experiment groups and the control group were cultured for 12 hours. The experimental groups were prepared by adding 10 mM NaNO.sub.2 and a CO-DH inhibitor to the bacteria cultured to the mid-exponential growth phase in the SMB-glucose medium (pH 5.5). The control group were prepared by dissolving 10 mM NaNO.sub.2 and a CO-DH inhibitor in a solvent (DMSO) to the bacteria. The experimental groups and control groups were appropriately diluted, and then plated on the SMB-glucose solid medium. The colony forming unit (CFU) value was calculated based on the number of obtained colonies. The calculated CFU value was expressed as a percentage of the control group. The results were shown in FIGS. 12a to 12c below.

[0100] As can be seen from FIGS. 12a to 12c below, the survival rate of the Mycobacterium sp. strain JC1 wild type was reduced in a concentration-dependent manner when treated with the compounds of Chemical Formulas 1 to 4 of 12.5 .mu.M to 50 .mu.M. It can be seen from the above results of compound treatment that the survival rate reduction of Mycobacterium sp. strain JC1 wild type was similar to that of the Mycobacterium sp. strain JC1 cutA mutant.

Example 3

Anti-Tuberculosis Test of Compounds

[0101] The anti-tuberculosis test of compounds was conducted using in an ex vivo binding model. Macrophages derived from mouse bone marrow cells were cultured and then infected with tuberculosis standard strain, followed by administration of each compound of different concentrations. The viable cell count of Mycobacterium tuberculosis remaining after culturing for 1 hour was measured for each of the compounds, and then compared with that of the control group.

[0102] The tuberculosis standard strain Mycobacterium tuberculosis H37Rv was seeded in 5 ml of the Middlebrook 7H9 (Difco) liquid medium, followed by culturing for 1 week; 5 ml of the culture liquid of Mycobacterium tuberculosis was seeded in 50 ml of the 7H9 medium, followed by culturing for 1 week; and 50 ml of the resultant culture liquid was seeded in 200 ml of the 7H9 medium, followed by culturing for 4 days. Then, the resultant culture liquid was left for 30 minutes, and only the supernatant was taken. A solution of glycerin was added thereto to a concentration of 10%, and then frozen-stored. The next day, the viable cell count of Mycobacterium tuberculosis under freezing storage was measured by ten-fold serial dilution. The Mycobacterium tuberculosis liquid under freezing storage was diluted with the Middlebrook 7H9 medium at a dilution ratio of 10,000 fold, 100,000 fold, and 1,000,000 fold. 0.1 ml of the diluted liquids were dropped onto the Middlebrook 7H10 (Difco) solid medium. The resultant medium was cultured at 37.degree. C. for 3 weeks. Then, the number of colony-forming units (CFU) was counted to determine the viable cell count in the Mycobacterium tuberculosis liquid.

[0103] For preparation of mouse macrophages, the mouse femur was severed and then both ends thereof were cut. A 1-ml syringe was filled with the RPMI-1640 medium (Gibco), which was then used to isolate and take marrow cells in the femur. Blood cells were removed from the taken marrow cells by a low-osmotic buffer, and then the number of marrow cells was measured using a microscope. After appropriate dilution with the RPMI-1640 medium, the marrow cells were seeded in a 96-well microplate at 100,000 cells per well. After culturing in a CO.sub.2 incubator at 37.degree. C. for 2 hours, cells other than the marrow cells were removed through exchange with a new RPMI-1640 medium. The medium was substituted with a culture supernatant of L929 cells, followed by culturing for 3 days. Again, the medium was substituted with a new culture supernatant of L929 cells, followed by culturing for 3 days.

[0104] In addition, as for infection with Mycobacterium tuberculosis, the frozen Mycobacterium tuberculosis was thawed, and then diluted with the RPMI-1630 medium to contain 1,000,000 viable cells per 0.2 ml of medium. The dilution liquid of Mycobacterium tuberculosis was filtered with a 5 .mu.M syringe filter, and then the Mycobacterium tuberculosis was dispensed in the prepared macrophage culture wells such that the Mycobacterium tuberculosis count was ten times the macrophages count. The culturing was performed at 37.degree. C. for 4 hours, followed by washing three times with the RPMI-640 medium and then dispensing of a new RPMI-1630 medium.

[0105] Then, the compounds of Chemical Formulas 1 to 4 were diluted with the RPMI-1640 medium by two-fold serial dilution, and then applied to respective wells to final concentrations of 100 .mu.M, 50 .mu.M, 25 .mu.M, 12.5 .mu.M, 6.25 .mu.M, 3.125 .mu.M, and 1.56 .mu.M. Here, one group consisted of three wells. After application of the compounds, the culturing was performed in a CO.sub.2 incubator at 37.degree. C. for 7 days. In addition, the cultured cells were washed three times with the RPMI-1640 medium, followed by an exchange with the RPMI-1640 medium containing 0.1% saponin (Sigma-Aldrich). After culturing for 10 minutes, the supernatant was removed. The Mycobacterium tuberculosis remaining in each well was appropriately diluted by ten-fold series dilution, and then seeded on the Middlebrook 7H10 (Difco) solid medium, followed by culturing for 3 weeks. The number of CFU of Mycobacterium tuberculosis was counted to determine the viable cell count of Mycobacterium tuberculosis. The results were shown in FIGS. 13a to 13c. Meanwhile, moxifloxacin (Bayer AG) and rifampicin (3-{[(4-Methyl-1-Piperazinyl)imino]methyl}rigamycin) were used as control groups.

[0106] As can be seen from FIGS. 13a to 13c, the survival rate of Mycobacterium tuberculosis in the marrow cell-derived macrophages was reduced by the treatment with the compounds in a concentration-dependent manner.

Example 4

Cytotoxicity Test of Compounds

[0107] In order to find whether the compounds kill Mycobacterium tuberculosis by their own toxicity or specifically act on the target to inhibit the growth of Mycobacterium tuberculosis, the toxicity of the compounds was tested by treating Mycobacterium tuberculosis with the compounds alone using the CellTiter 96 Non-Radioactive Cell Proliferation Assay kit form Promega, USA.

[0108] Specifically, the Vero cell line under freezing storage (ATCC CCL-81) was thawed, and cultured in the DMEM medium (Gibco) for 4 days. The number of serially passaged cells was measured, and then the Vero cells were seeded in a 96-well microplate at 10,000 cells per well. The cells were cultured in the presence of 5% CO.sub.2 at 37.degree. C. overnight. Then, the compounds of Chemical Formulas 1 to 4 were diluted with the RPMI-1640 medium by two-fold serial dilution, and then applied to respective wells to final concentrations of 100 .mu.M, 50 .mu.M, 25 .mu.M, 12.5 .mu.M, 6.25 .mu.M, 3.125 .mu.M, and 1.56 .mu.M. Here, one group consisted of three wells. After the compounds were applied, the cells were cultured in a CO.sub.2 incubator at 37.degree. C. for 3 days.

[0109] Cytotoxicity was measured according to the method of Promega Inc., and 15 .mu.l of a staining solution was applied to each well of the 96-well plate. The cells were incubated in a CO.sub.2 incubator at 37.degree. C. for 4 hours, and then 100 .mu.l of a quiescent solution was applied thereto. The absorbance of each well was measured at 570 nm using an absorbance measurement equipment from Molecular Devices. The absorbance values of wells not containing the compounds of Chemical Formulas 1 to 4 were compared with those of wells containing the compounds of Chemical Formulas 1 to 4 to determine the inhibition (%). The correlation between inhibition and concentration was calculated using the Prism software from Graphpad to determine IC.sub.50 (concentration at 50% inhibition) value. The results for the Vero cell line and the marrow cell-derived macrophages were summarized in Table 2 below. The marrow cell-derived macrophages were prepared by the method as described in Example 3 above.

TABLE-US-00002 TABLE 2 IC.sub.50 (.mu.M) IC.sub.50 (.mu.M) -- (Vero cell line) (macrophages) Chemical Formula 1 (115024) 75.17 >100 Chemical Formula 2 (114976) 36.41 >100 Chemical Formula 3 (114991) 108.6 >100 Chemical Formula 4 (127999) 157.5 >100

[0110] The results for the Mycobacterium sp. strain JC1 wild type were summarized in Table 3 below.

TABLE-US-00003 TABLE 3 Compound analog + JC 1 wild type -- (percentage (%) of CFU inhibition) Concentration 12.5 .mu.M 25 .mu.M 50 .mu.M Chemical Formula 1 (115024) 0 2 6 Chemical Formula 2 (114976) 3 9 12 Chemical Formula 3 (114991) 4 2 8 Chemical Formula 4 (127999) 2 4 16

[0111] As can be determined from Tables 2 and 3 above, the compounds do not kill Mycobacterium tuberculosis by their own toxicity, but specifically act on the target CO-DH to inhibit the growth of Mycobacterium tuberculosis.

[0112] Although the present invention has been described in detail with reference to the specific features, it will be apparent to those skilled in the art that this description is only for a preferred embodiment and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 7 <210> SEQ ID NO 1 <400> SEQUENCE: 1 000 <210> SEQ ID NO 2 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: cutA-rev <400> SEQUENCE: 2 cagatcggcg gggtcgctct g 21 <210> SEQ ID NO 3 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: cutR-for <400> SEQUENCE: 3 gagccccgac gacgttcggg 20 <210> SEQ ID NO 4 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: orf1-for <400> SEQUENCE: 4 ggcgtgggta tggaggtctt 20 <210> SEQ ID NO 5 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: orf2-rev <400> SEQUENCE: 5 gtcactcgtg accgcagcat 20 <210> SEQ ID NO 6 <211> LENGTH: 797 <212> TYPE: PRT <213> ORGANISM: Mycobacterium sp. JC1 <400> SEQUENCE: 6 Met Thr Thr Ala Asp Val Ile Glu Asp Asn Glu Thr Ala Asp Asn Asp 1 5 10 15 Lys Lys Pro Cys Cys Tyr Gly Arg Met Leu Arg Lys Glu Asp Pro Arg 20 25 30 Phe Ile Arg Gly Arg Gly Asn Tyr Val Asp Asp Val Gln Leu Pro Gly 35 40 45 Met Leu His Leu Ala Ile Leu Arg Ser Pro Phe Ala His Ala Asn Ile 50 55 60 Val Ser Val Asp Ile Ser Ala Ala Gln Ala His Pro Lys Val Lys Leu 65 70 75 80 Val Val Thr Gly Ala Met Leu Ala Glu Lys Gly Leu Ala Val Met Pro 85 90 95 Thr Leu Ser Asn Asp Val Gln Ala Val Leu Ala Thr Asp Arg Val Arg 100 105 110 Phe Gln Gly Gln Glu Val Ala Phe Val Val Ala Glu Asp Arg Tyr Ser 115 120 125 Ala Arg Asp Ala Leu Glu Leu Ile Asp Val Glu Tyr Glu Ala Leu Asp 130 135 140 Pro Val Ile Asp Val Arg Lys Ala Leu Asp Pro Gly Ala Glu Val Ile 145 150 155 160 Arg Thr Asp Leu Glu Gly Lys Thr Asp Asn His Cys Phe Asp Val Glu 165 170 175 Thr Gly Asp Ala Ala Ala Thr Asp Ala Ala Phe Ala Lys Ala Asp Val 180 185 190 Val Val Thr Gln Glu Ile Ile Tyr Pro Arg Val His Pro Cys Pro Met 195 200 205 Glu Thr Cys Gly Ala Val Ala Asp Leu Asp Pro Val Ser Gly Lys Leu 210 215 220 Arg Leu Val Ser Thr Thr Gln Ala Pro His Ala His Arg Thr Leu Tyr 225 230 235 240 Ala Leu Val Ala Gly Leu Pro Glu His Lys Ile Gln Val Ile Ser Pro 245 250 255 Asp Ile Gly Gly Gly Phe Gly Asn Lys Val Pro Ile Tyr Pro Gly Tyr 260 265 270 Val Cys Ala Ile Val Gly Ser Leu Leu Leu Gly Lys Pro Val Lys Trp 275 280 285 Met Glu Asp Arg Ala Glu His Leu Met Ser Thr Gly Phe Ala Arg Asp 290 295 300 Tyr Val Met Leu Gly Glu Ile Ala Ala Thr Lys Asp Gly Lys Ile Leu 305 310 315 320 Ala Ile Arg Ser Asn Val Leu Ala Asp His Gly Ala Phe Asn Gly Thr 325 330 335 Ala Ala Pro Val Lys Tyr Pro Ala Gly Phe Phe Gly Val Phe Thr Gly 340 345 350 Ser Tyr Asp Ile Glu Ala Ala Tyr Cys His Met Thr Ala Val Tyr Thr 355 360 365 Asn Lys Ala Pro Gly Gly Val Ala Tyr Ala Cys Ser Phe Arg Ile Thr 370 375 380 Glu Ala Val Tyr Phe Val Glu Arg Leu Val Asp Cys Leu Ala Phe Asp 385 390 395 400 Leu Arg Met Asp Pro Val Glu Leu Arg Leu Arg Asn Leu Leu Lys Pro 405 410 415 Glu Gln Phe Pro Tyr Lys Ser Lys Thr Gly Val Val Tyr Asp Ser Gly 420 425 430 Asp Tyr Glu Lys Thr Leu Arg Leu Ala Met Asp Met Ile Gly Tyr Asp 435 440 445 Gly Leu Arg Lys Glu Gln Ala Glu Lys Arg Ala Arg Gly Glu Leu Met 450 455 460 Gly Ile Gly Val Ser Phe Phe Thr Glu Ala Val Gly Ala Gly Pro Arg 465 470 475 480 Lys Asp Met Asp Ile Leu Gly Leu Gly Met Ala Asp Gly Cys Glu Leu 485 490 495 Arg Val His Pro Thr Gly Lys Ala Val Val Arg Leu Ser Val Gln Thr 500 505 510 Gln Gly Gln Gly His Glu Thr Thr Phe Ala Gln Ile Val Ala Glu Glu 515 520 525 Leu Gly Ile Pro Pro Glu Asp Ile Asp Val Val His Gly Asp Thr Asp 530 535 540 Gln Thr Pro Phe Gly Leu Gly Thr Tyr Gly Ser Arg Ser Thr Pro Val 545 550 555 560 Ser Gly Ala Ala Ala Ala Leu Val Ala Arg Lys Val Arg Asp Lys Ala 565 570 575 Lys Ile Ile Ala Ser Gly Met Leu Glu Ala Ser Val Ala Asp Leu Glu 580 585 590 Val Glu Lys Gly Ser Phe Arg Val Lys Gly Asp Pro Ala Ala Ser Val 595 600 605 Thr Ile Gln Asp Ile Ala Met Arg Ala His Gly Ala Ala Asp Leu Pro 610 615 620 Glu Gly Leu Glu Gly Gly Leu Asp Ala Gln Val Cys Tyr Asn Pro Glu 625 630 635 640 Asn Met Thr Tyr Pro Tyr Gly Ala Tyr Phe Cys Val Val Asp Val Asp 645 650 655 Pro Gly Thr Ala Gln Val Lys Val Arg Arg Phe Leu Ala Val Asp Asp 660 665 670 Cys Gly Thr Arg Ile Asn Pro Met Ile Ile Glu Gly Gln Val His Gly 675 680 685 Gly Ile Val Asp Gly Ile Gly Met Ala Leu Met Glu Met Ile Ala Phe 690 695 700 Asp Glu Gln Gly Asn Cys Leu Gly Gly Ser Leu Met Asp Tyr Leu Ile 705 710 715 720 Pro Thr Ala Met Glu Val Pro His Phe Glu Thr Gly His Thr Val Thr 725 730 735 Pro Ser Pro His His Pro Ile Gly Ala Lys Gly Val Gly Glu Ser Ala 740 745 750 Thr Val Gly Ser Pro Pro Ala Val Val Asn Ala Val Val Asp Ala Leu 755 760 765 Ala Pro Phe Gly Val Arg His Ala Asp Met Pro Leu Asn Pro Ser Arg 770 775 780 Val Val Glu Ala Met Gln Gly Arg Ala Thr Pro Pro Ile 785 790 795 <210> SEQ ID NO 7 <211> LENGTH: 330 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CutA with a deletion of Mycobacterium sp. strain JC1 cutA- mutant <400> SEQUENCE: 7 Met Thr Thr Ala Asp Val Ile Glu Asp Asn Glu Thr Ala Asp Asn Asp 1 5 10 15 Lys Lys Pro Cys Cys Tyr Gly Arg Met Leu Arg Lys Glu Asp Pro Arg 20 25 30 Phe Ile Arg Gly Arg Gly Asn Tyr Val Asp Asp Val Gln Leu Pro Gly 35 40 45 Met Leu His Leu Ala Ile Leu Arg Ser Pro Phe Ala His Ala Asn Ile 50 55 60 Val Ser Val Asp Ile Asp Val Val His Gly Asp Thr Asp Gln Thr Pro 65 70 75 80 Phe Gly Leu Gly Thr Tyr Gly Ser Arg Ser Thr Pro Val Ser Gly Ala 85 90 95 Ala Ala Ala Leu Val Ala Arg Lys Val Arg Asp Lys Ala Lys Ile Ile 100 105 110 Ala Ser Gly Met Leu Glu Ala Ser Val Ala Asp Leu Glu Val Glu Lys 115 120 125 Gly Ser Phe Arg Val Lys Gly Asp Pro Ala Ala Ser Val Thr Ile Gln 130 135 140 Asp Ile Ala Met Arg Ala His Gly Ala Ala Asp Leu Pro Glu Gly Leu 145 150 155 160 Glu Gly Gly Leu Asp Ala Gln Val Cys Tyr Asn Pro Glu Asn Met Thr 165 170 175 Tyr Pro Tyr Gly Ala Tyr Phe Cys Val Val Asp Val Asp Pro Gly Thr 180 185 190 Ala Gln Val Lys Val Arg Arg Phe Leu Ala Val Asp Asp Cys Gly Thr 195 200 205 Arg Ile Asn Pro Met Ile Ile Glu Gly Gln Val His Gly Gly Ile Val 210 215 220 Asp Gly Ile Gly Met Ala Leu Met Glu Met Ile Ala Phe Asp Glu Gln 225 230 235 240 Gly Asn Cys Leu Gly Gly Ser Leu Met Asp Tyr Leu Ile Pro Thr Ala 245 250 255 Met Glu Val Pro His Phe Glu Thr Gly His Thr Val Thr Pro Ser Pro 260 265 270 His His Pro Ile Gly Ala Lys Gly Val Gly Glu Ser Ala Thr Val Gly 275 280 285 Ser Pro Pro Ala Val Val Asn Ala Val Val Asp Ala Leu Ala Pro Phe 290 295 300 Gly Val Arg His Ala Asp Met Pro Leu Asn Pro Ser Arg Val Val Glu 305 310 315 320 Ala Met Gln Gly Arg Ala Thr Pro Pro Ile 325 330

1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 7 <210> SEQ ID NO 1 <400> SEQUENCE: 1 000 <210> SEQ ID NO 2 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: cutA-rev <400> SEQUENCE: 2 cagatcggcg gggtcgctct g 21 <210> SEQ ID NO 3 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: cutR-for <400> SEQUENCE: 3 gagccccgac gacgttcggg 20 <210> SEQ ID NO 4 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: orf1-for <400> SEQUENCE: 4 ggcgtgggta tggaggtctt 20 <210> SEQ ID NO 5 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: orf2-rev <400> SEQUENCE: 5 gtcactcgtg accgcagcat 20 <210> SEQ ID NO 6 <211> LENGTH: 797 <212> TYPE: PRT <213> ORGANISM: Mycobacterium sp. JC1 <400> SEQUENCE: 6 Met Thr Thr Ala Asp Val Ile Glu Asp Asn Glu Thr Ala Asp Asn Asp 1 5 10 15 Lys Lys Pro Cys Cys Tyr Gly Arg Met Leu Arg Lys Glu Asp Pro Arg 20 25 30 Phe Ile Arg Gly Arg Gly Asn Tyr Val Asp Asp Val Gln Leu Pro Gly 35 40 45 Met Leu His Leu Ala Ile Leu Arg Ser Pro Phe Ala His Ala Asn Ile 50 55 60 Val Ser Val Asp Ile Ser Ala Ala Gln Ala His Pro Lys Val Lys Leu 65 70 75 80 Val Val Thr Gly Ala Met Leu Ala Glu Lys Gly Leu Ala Val Met Pro 85 90 95 Thr Leu Ser Asn Asp Val Gln Ala Val Leu Ala Thr Asp Arg Val Arg 100 105 110 Phe Gln Gly Gln Glu Val Ala Phe Val Val Ala Glu Asp Arg Tyr Ser 115 120 125 Ala Arg Asp Ala Leu Glu Leu Ile Asp Val Glu Tyr Glu Ala Leu Asp 130 135 140 Pro Val Ile Asp Val Arg Lys Ala Leu Asp Pro Gly Ala Glu Val Ile 145 150 155 160 Arg Thr Asp Leu Glu Gly Lys Thr Asp Asn His Cys Phe Asp Val Glu 165 170 175 Thr Gly Asp Ala Ala Ala Thr Asp Ala Ala Phe Ala Lys Ala Asp Val 180 185 190 Val Val Thr Gln Glu Ile Ile Tyr Pro Arg Val His Pro Cys Pro Met 195 200 205 Glu Thr Cys Gly Ala Val Ala Asp Leu Asp Pro Val Ser Gly Lys Leu 210 215 220 Arg Leu Val Ser Thr Thr Gln Ala Pro His Ala His Arg Thr Leu Tyr 225 230 235 240 Ala Leu Val Ala Gly Leu Pro Glu His Lys Ile Gln Val Ile Ser Pro 245 250 255 Asp Ile Gly Gly Gly Phe Gly Asn Lys Val Pro Ile Tyr Pro Gly Tyr 260 265 270 Val Cys Ala Ile Val Gly Ser Leu Leu Leu Gly Lys Pro Val Lys Trp 275 280 285 Met Glu Asp Arg Ala Glu His Leu Met Ser Thr Gly Phe Ala Arg Asp 290 295 300 Tyr Val Met Leu Gly Glu Ile Ala Ala Thr Lys Asp Gly Lys Ile Leu 305 310 315 320 Ala Ile Arg Ser Asn Val Leu Ala Asp His Gly Ala Phe Asn Gly Thr 325 330 335 Ala Ala Pro Val Lys Tyr Pro Ala Gly Phe Phe Gly Val Phe Thr Gly 340 345 350 Ser Tyr Asp Ile Glu Ala Ala Tyr Cys His Met Thr Ala Val Tyr Thr 355 360 365 Asn Lys Ala Pro Gly Gly Val Ala Tyr Ala Cys Ser Phe Arg Ile Thr 370 375 380 Glu Ala Val Tyr Phe Val Glu Arg Leu Val Asp Cys Leu Ala Phe Asp 385 390 395 400 Leu Arg Met Asp Pro Val Glu Leu Arg Leu Arg Asn Leu Leu Lys Pro 405 410 415 Glu Gln Phe Pro Tyr Lys Ser Lys Thr Gly Val Val Tyr Asp Ser Gly 420 425 430 Asp Tyr Glu Lys Thr Leu Arg Leu Ala Met Asp Met Ile Gly Tyr Asp 435 440 445 Gly Leu Arg Lys Glu Gln Ala Glu Lys Arg Ala Arg Gly Glu Leu Met 450 455 460 Gly Ile Gly Val Ser Phe Phe Thr Glu Ala Val Gly Ala Gly Pro Arg 465 470 475 480 Lys Asp Met Asp Ile Leu Gly Leu Gly Met Ala Asp Gly Cys Glu Leu 485 490 495 Arg Val His Pro Thr Gly Lys Ala Val Val Arg Leu Ser Val Gln Thr 500 505 510 Gln Gly Gln Gly His Glu Thr Thr Phe Ala Gln Ile Val Ala Glu Glu 515 520 525 Leu Gly Ile Pro Pro Glu Asp Ile Asp Val Val His Gly Asp Thr Asp 530 535 540 Gln Thr Pro Phe Gly Leu Gly Thr Tyr Gly Ser Arg Ser Thr Pro Val 545 550 555 560 Ser Gly Ala Ala Ala Ala Leu Val Ala Arg Lys Val Arg Asp Lys Ala 565 570 575 Lys Ile Ile Ala Ser Gly Met Leu Glu Ala Ser Val Ala Asp Leu Glu 580 585 590 Val Glu Lys Gly Ser Phe Arg Val Lys Gly Asp Pro Ala Ala Ser Val 595 600 605 Thr Ile Gln Asp Ile Ala Met Arg Ala His Gly Ala Ala Asp Leu Pro 610 615 620 Glu Gly Leu Glu Gly Gly Leu Asp Ala Gln Val Cys Tyr Asn Pro Glu 625 630 635 640 Asn Met Thr Tyr Pro Tyr Gly Ala Tyr Phe Cys Val Val Asp Val Asp 645 650 655 Pro Gly Thr Ala Gln Val Lys Val Arg Arg Phe Leu Ala Val Asp Asp 660 665 670 Cys Gly Thr Arg Ile Asn Pro Met Ile Ile Glu Gly Gln Val His Gly 675 680 685 Gly Ile Val Asp Gly Ile Gly Met Ala Leu Met Glu Met Ile Ala Phe 690 695 700 Asp Glu Gln Gly Asn Cys Leu Gly Gly Ser Leu Met Asp Tyr Leu Ile 705 710 715 720 Pro Thr Ala Met Glu Val Pro His Phe Glu Thr Gly His Thr Val Thr 725 730 735 Pro Ser Pro His His Pro Ile Gly Ala Lys Gly Val Gly Glu Ser Ala 740 745 750 Thr Val Gly Ser Pro Pro Ala Val Val Asn Ala Val Val Asp Ala Leu 755 760 765 Ala Pro Phe Gly Val Arg His Ala Asp Met Pro Leu Asn Pro Ser Arg 770 775 780 Val Val Glu Ala Met Gln Gly Arg Ala Thr Pro Pro Ile 785 790 795 <210> SEQ ID NO 7 <211> LENGTH: 330 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CutA with a deletion of Mycobacterium sp. strain JC1 cutA- mutant <400> SEQUENCE: 7 Met Thr Thr Ala Asp Val Ile Glu Asp Asn Glu Thr Ala Asp Asn Asp 1 5 10 15 Lys Lys Pro Cys Cys Tyr Gly Arg Met Leu Arg Lys Glu Asp Pro Arg 20 25 30 Phe Ile Arg Gly Arg Gly Asn Tyr Val Asp Asp Val Gln Leu Pro Gly 35 40 45 Met Leu His Leu Ala Ile Leu Arg Ser Pro Phe Ala His Ala Asn Ile 50 55 60 Val Ser Val Asp Ile Asp Val Val His Gly Asp Thr Asp Gln Thr Pro 65 70 75 80 Phe Gly Leu Gly Thr Tyr Gly Ser Arg Ser Thr Pro Val Ser Gly Ala 85 90 95 Ala Ala Ala Leu Val Ala Arg Lys Val Arg Asp Lys Ala Lys Ile Ile 100 105 110

Ala Ser Gly Met Leu Glu Ala Ser Val Ala Asp Leu Glu Val Glu Lys 115 120 125 Gly Ser Phe Arg Val Lys Gly Asp Pro Ala Ala Ser Val Thr Ile Gln 130 135 140 Asp Ile Ala Met Arg Ala His Gly Ala Ala Asp Leu Pro Glu Gly Leu 145 150 155 160 Glu Gly Gly Leu Asp Ala Gln Val Cys Tyr Asn Pro Glu Asn Met Thr 165 170 175 Tyr Pro Tyr Gly Ala Tyr Phe Cys Val Val Asp Val Asp Pro Gly Thr 180 185 190 Ala Gln Val Lys Val Arg Arg Phe Leu Ala Val Asp Asp Cys Gly Thr 195 200 205 Arg Ile Asn Pro Met Ile Ile Glu Gly Gln Val His Gly Gly Ile Val 210 215 220 Asp Gly Ile Gly Met Ala Leu Met Glu Met Ile Ala Phe Asp Glu Gln 225 230 235 240 Gly Asn Cys Leu Gly Gly Ser Leu Met Asp Tyr Leu Ile Pro Thr Ala 245 250 255 Met Glu Val Pro His Phe Glu Thr Gly His Thr Val Thr Pro Ser Pro 260 265 270 His His Pro Ile Gly Ala Lys Gly Val Gly Glu Ser Ala Thr Val Gly 275 280 285 Ser Pro Pro Ala Val Val Asn Ala Val Val Asp Ala Leu Ala Pro Phe 290 295 300 Gly Val Arg His Ala Asp Met Pro Leu Asn Pro Ser Arg Val Val Glu 305 310 315 320 Ala Met Gln Gly Arg Ala Thr Pro Pro Ile 325 330

Claims

1-8. (canceled)

9. A method for preventing or treating tuberculosis, the method comprising administering to a subject a pharmaceutical composition containing: (a) a pharmaceutically effective amount of a compound represented by General Formula 1 below; and (b) a pharmaceutically acceptable carrier: ##STR00008## wherein in Formula 1, R.sub.1 is ##STR00009## where R.sub.3 and R.sub.4 each are independently H, hydroxyl, halogen, C.sub.1-C.sub.10 alkyl, or C.sub.3-C.sub.15 cycloalky; R.sub.2 is H, a hydroxyl, halogen, C.sub.1-C.sub.10 alkyl, C.sub.3-C.sub.15 cycloalkyl, C.sub.2-C.sub.10 alkenyl, or C.sub.1-C.sub.8 alkoxy; A and B each are independently CH or N; and n is an integer of 1 to 5.

10. The method of claim 9, wherein the compound represented by Formula 1 is a compound represented by Formula 2 below: ##STR00010## wherein in Formula 2, R.sub.2 is H, hydroxyl, halogen, or C.sub.1-C.sub.10 alkyl; A and B each are independently CH or N; n is an integer of 1 to 3; and R.sub.3 is H, hydroxyl, halogen, or C.sub.1-C.sub.10 alkyl.

11. The method of claim 9, wherein the compound represented by Formula 1 is a compound represented by Formula 3 below: ##STR00011## wherein in Formula 3, R.sub.2 is H, hydroxyl, halogen, or C.sub.1-C.sub.10 alkyl; A and B each are independently CH or N; n is an integer of 1 to 3; and R.sub.3 and R.sub.4 each are independently H, hydroxyl, halogen, or C.sub.1-C.sub.10 alkyl.

12. The method of claim 10, wherein the compound represented by Formula 2 is a compound represented by Formula 3 below: ##STR00012##

13. The method of claim 11, wherein the compound represented by Formula 3 is a compound selected from the group consisting of Formulas 5 to 7 below: ##STR00013##

14. The method of claim 9, wherein the compound inhibits the transcription of carbon monoxide dehydrogenase (CO-DH) genes.

15. The method of claim 9, wherein the compound inhibits the expression of CO-DH genes.

16. The method of claim 9, wherein the tuberculosis is eye tuberculosis, skin tuberculosis, adrenal tuberculosis, renal tuberculosis, epididymal tuberculosis, lymphatic gland tuberculosis, laryngeal tuberculosis, middle ear tuberculosis, intestinal tuberculosis, multidrug-resistant tuberculosis, pulmonary tuberculosis, sputum tuberculosis, bone tuberculosis, throat tuberculosis, lymphatic tuberculosis, lung deficiency, breast tuberculosis, or spinal tuberculosis.